ImmunoPrecise Antibodies Ltd.

TSXV:IPA 株式レポート

時価総額:CA$162.1m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

ImmunoPrecise Antibodies バランスシートの健全性

財務の健全性 基準チェック /46

主要情報

0%

負債資本比率

CA$0

負債

インタレスト・カバレッジ・レシオn/a
現金CA$19.24m
エクイティCA$66.24m
負債合計CA$13.70m
総資産CA$79.94m

財務の健全性に関する最新情報

Recent updates

We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Oct 20
We Think ImmunoPrecise Antibodies (CVE:IPA) Needs To Drive Business Growth Carefully

Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Dec 23
Earnings Update: ImmunoPrecise Antibodies Ltd. (CVE:IPA) Just Reported And Analysts Are Boosting Their Estimates

Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

Nov 25
Is ImmunoPrecise Antibodies (CVE:IPA) Using Debt In A Risky Way?

財務状況分析

短期負債: IPA's short term assets (CA$27.1M) exceed its short term liabilities (CA$5.4M).

長期負債: IPA's short term assets (CA$27.1M) exceed its long term liabilities (CA$8.3M).


デット・ツー・エクイティの歴史と分析

負債レベル: IPA is debt free.

負債の削減: IPA had no debt 5 years ago.


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: IPA has less than a year of cash runway based on its current free cash flow.

キャッシュランウェイの予測: IPA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36% each year


健全な企業の発掘